Aethlon Medical, Inc. reported its financial results for the fiscal first quarter ended June 30, 2025, on August 13, 2025. As of June 30, 2025, the company had a cash balance of approximately $3.8 million.
Consolidated operating expenses for the quarter decreased by approximately $800,000, or 31.6%, to $1.8 million compared to $2.6 million for the same period in 2024. This reduction was primarily driven by lower payroll and related expenses, professional fees, and general and administrative costs. However, management explicitly stated that existing cash is "not sufficient to fund the Company’s operations for at least twelve months," leading to "substantial doubt about the Company’s ability to continue as a going concern."
In clinical updates, the first treatment cohort in the Australian oncology trial was successfully completed, and the Data Safety Monitoring Board recommended advancing to Cohort 2. Initial observations from central lab analysis of Cohort 1 samples are expected in September 2025. The company also made a strategic decision not to proceed with the oncology study in India, citing extended timelines and cost considerations, to focus resources on the Australian trial. Preclinical data on Long COVID was presented at the Keystone Symposium, demonstrating the Hemopurifier's ability to bind extracellular vesicles from Long COVID patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.